PDCD1 and colorectal carcinoma: The emergence of immunotherapy has transformed the management of CRC, particularly in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors, where PD-1 inhibitors such as pembrolizumab and nivolumab demonstrate durable responses.